TORONTO--(BUSINESS WIRE)--XVIVO, a global medtech company in the organ transplant industry, today announced late-breaking preliminary data from the PRESERVE Trial (NCT05881278) evaluating hypothermic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results